TITLE:
Advanced Undifferentiated Endometrial Carcinoma with No Evidence of Disease after Neoadjuvant Chemotherapy: A Case Report
AUTHORS:
Cassandra L. Presti, Payam Katebi Kashi, Christopher M. Tarney, Ruchi Garg
KEYWORDS:
Neoadjuvant Chemotherapy, Undifferentiated Endometrial Carcinoma
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.10 No.11,
November
16,
2020
ABSTRACT: Background: Neoadjuvant chemotherapy is used in gynecologic malignancies as primary
treatment for advanced disease and has demonstrated improvement in survival
rates. However, the data for use in endometrial cancer is limited. Case: This is a case of stage IV endometrial undifferentiated carcinoma with complete
response to four cycles of neoadjuvant chemotherapy (carboplatin/paclitaxel)
and no evidence of disease during the interval debulking surgery
(robotic-assisted total laparoscopic hysterectomy with bilateral
salpingoophorectomy, pelvic and paraaortic lymph node dissection, and
cystoscopy). Conclusion: Complete response to neoadjuvant chemotherapy
prior to interval debulking surgery is only reported in a limited number of
cases, and even less common in advanced stage high-grade endometrial cancers.
The use of neoadjuvant chemotherapy may reduce tumor burden, increase
opportunities for optimal debulking, and have an impact on survival. Further
research is needed to understand the potential for neoadjuvant chemotherapy in
these patients.